Uemura Y, Lee T C, Snyder F
Medical Sciences Division, Oak Ridge Associated Universities, Tennessee 37831-0117.
J Biol Chem. 1991 May 5;266(13):8268-72.
The remodeling pathway for the biosynthesis of platelet-activating factor (PAF) consists of the following reaction sequence: alkylacylglycerophosphocholine----lyso-PAF----PAF. Results presented in this article describe a novel transacylase activity that generates the lyso-PAF intermediate, which can then be acetylated to form PAF. Ethanolamine-containing lysoplasmalogens, 1-acyl-2-lyso-sn-glycero-3-phosphoethanolamine, alkyllysophosphoethanolamine, unlabeled lyso-PAF, 1-acyl-2-lyso-GPC, where GPC is sn-glycero-3-phosphocholine, and choline-containing lysoplasmalogens were all able to stimulate the formation of [3H]lyso-PAF from a [3H]alkylacyl-GPC precursor pool associated with HL-60 cell (granulocytic type) membranes. Other glycerolipids containing free hydroxyl groups (3-alkyl-2-lyso-sn-glycero-1-phosphocholine, lysophosphatidylserine, lysophosphatidylinositol, diacylglycerols, alkylglycerols, and monoacylglycerols), cholesterol, phosphatidylcholine, and phosphatidylethanolamine had no stimulatory effect on the release of [3H]lyso-PAF from the prelabeled membranes under identical incubation conditions. The observed transacylase reaction is directly coupled to PAF production, since the addition of a lysoethanolamine plasmalogen preparation to HL-60 membranes in the presence of [14C]acetyl-CoA stimulated PAF formation; under these conditions the lysoethanolamine plasmalogen was acylated. The transacylase responsible for the release of lyso-PAF from the membrane-associated alkylacyl-GPC was not affected by Ca2+, EGTA, or a known phospholipase A2 inhibitor, p-bromophenacyl bromide. The fact that the unnatural analog of lyso-PAF, lysophosphatidylserine, and lysophosphatidylinositol did not influence transacylase activity, whereas detergents such as deoxycholate and Triton X-100 inhibited the activity, demonstrated the observed stimulatory effects of the choline- and ethanolamine-containing lysophospholipids on the formation of [3H]lyso-PAF from [3H]alkylacyl-GPC were not due to any detergent property of these lysophospholipids. Thus, we conclude a CoA-independent transacylase (possessing phospholipase A2/acyltransferase activities) can be responsible for the formation of the lyso-PAF intermediate in the remodeling route of PAF biosynthesis.
血小板活化因子(PAF)生物合成的重塑途径由以下反应序列组成:烷基酰基甘油磷酸胆碱→溶血PAF→PAF。本文给出的结果描述了一种产生溶血PAF中间体的新型转酰基酶活性,该中间体随后可被乙酰化形成PAF。含乙醇胺的溶血缩醛磷脂、1-酰基-2-溶血-sn-甘油-3-磷酸乙醇胺、烷基溶血磷酸乙醇胺、未标记的溶血PAF、1-酰基-2-溶血-GPC(其中GPC是sn-甘油-3-磷酸胆碱)以及含胆碱的溶血缩醛磷脂均能够刺激与HL-60细胞(粒细胞型)膜相关的[3H]烷基酰基-GPC前体库形成[3H]溶血PAF。在相同孵育条件下,其他含有游离羟基的甘油脂(3-烷基-2-溶血-sn-甘油-1-磷酸胆碱、溶血磷脂酰丝氨酸、溶血磷脂酰肌醇、二酰基甘油、烷基甘油和单酰基甘油)、胆固醇、磷脂酰胆碱和磷脂酰乙醇胺对预标记膜释放[3H]溶血PAF没有刺激作用。观察到的转酰基酶反应与PAF的产生直接相关,因为在[14C]乙酰辅酶A存在下,向HL-60膜中添加溶血乙醇胺缩醛磷脂制剂可刺激PAF的形成;在这些条件下,溶血乙醇胺缩醛磷脂被酰化。负责从膜相关的烷基酰基-GPC释放溶血PAF的转酰基酶不受Ca2+、乙二醇双四乙酸(EGTA)或已知的磷脂酶A2抑制剂对溴苯甲酰溴的影响。溶血PAF的非天然类似物、溶血磷脂酰丝氨酸和溶血磷脂酰肌醇不影响转酰基酶活性,而脱氧胆酸盐和吐温X-100等去污剂抑制该活性,这表明观察到的含胆碱和乙醇胺的溶血磷脂对[3H]烷基酰基-GPC形成[3H]溶血PAF的刺激作用并非由于这些溶血磷脂的任何去污剂性质。因此,我们得出结论,一种不依赖辅酶A的转酰基酶(具有磷脂酶A2/酰基转移酶活性)可能负责PAF生物合成重塑途径中溶血PAF中间体的形成。